Bladder Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bladder Cancer – Pipeline Review, H2 2016’, provides an overview of the Bladder Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bladder Cancer

The report reviews pipeline therapeutics for Bladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bladder Cancer therapeutics and enlists all their major and minor projects

The report assesses Bladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bladder Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bladder Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Agenus Inc

Altor BioScience Corporation

AndroScience Corporation

APIM Therapeutics AS

Arno Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals Inc

Aura Biosciences, Inc.

AVEO Pharmaceuticals, Inc.

Azaya Therapeutics, Inc.

Bavarian Nordic A/S

Bayer AG

BioCancell Ltd

Biomics Biotechnologies Co., Ltd.

Bioncotech Therapeutics SL

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellceutix Corporation

Celldex Therapeutics, Inc.

Celprogen, Inc.

Celsion Corporation

Codagenix, Inc.

Cold Genesys, Inc.

Corvus Pharmaceuticals Inc

CytomX Therapeutics, Inc.

DormaTarg, Inc.

Eisai Co., Ltd.

Eleven Biotherapeutics Inc.

Eli Lilly and Company

Elsalys Biotech SAS

enGene, Inc

Esperance Pharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Gene Signal International SA

Genmab A/S

GlaxoSmithKline Plc

H3 Biomedicine Inc.

Hamlet Pharma AB

Heat Biologics, Inc.

HEC Pharm Co., Ltd.

Hutchison MediPharma Limited

Idera Pharmaceuticals, Inc.

ImmuNext, Inc.

Immunocore Limited

Immunomedics, Inc.

Immupharma Plc

InteRNA Technologies B.V.

Johnson & Johnson

LipoMedix Pharmaceutical Inc.

MacroGenics, Inc.

MaxiVAX SA

Meabco A/S

Medicenna Therapeutics, Inc.

MedImmune LLC

Merck & Co., Inc.

Merck KGaA

Mirati Therapeutics Inc.

Mirna Therapeutics, Inc.

Miyarisan Pharmaceutical Company, Ltd

Moleculin Biotech Inc

NanoCarrier Co., Ltd.

Nektar Therapeutics

NuCana BioMed Limited

Omeros Corporation

Oncogenex Pharmaceuticals, Inc.

Oncolytics Biotech Inc.

OncoTherapy Science, Inc.

Ono Pharmaceutical Co., Ltd.

Optimum Therapeutics, LLC

Pfizer Inc.

Pharma Mar, S.A.

Philogen S.p.A.

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PsiOxus Therapeutics Limited

Rexahn Pharmaceuticals, Inc.

Rodos BioTarget GmbH

Sanofi

Savoy Pharmaceuticals, Inc.

Serometrix, LLC

Shionogi & Co., Ltd.

Sillajen Biotherapeutics

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Sun Pharma Advanced Research Co Ltd

Synovo GmbH

Taiwan Liposome Company, Ltd.

Tara Immuno-Oncology Therapeutics LLC

Taris Biomedical LLC

Telormedix SA

TesoRx Pharma LLC

Theravectys SA

Theryte Limited

Transgene SA

UroGen Pharmaceuticals, Ltd.

Vakzine Projekt Management GmbH

Vault Pharma Inc.

Vaxeal Holding SA

Vaxiion Therapeutics, Inc.

Viralytics Ltd.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Bladder Cancer Overview 8

Therapeutics Development 9

Bladder Cancer - Therapeutics under Development by Companies 11

Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 19

Bladder Cancer - Pipeline Products Glance 20

Bladder Cancer - Products under Development by Companies 23

Bladder Cancer - Products under Investigation by Universities/Institutes 34

Bladder Cancer - Companies Involved in Therapeutics Development 35

Bladder Cancer - Therapeutics Assessment 144

Drug Profiles 167

Bladder Cancer - Dormant Projects 693

Bladder Cancer - Discontinued Products 703

Bladder Cancer - Product Development Milestones 704

Appendix 721

List of Tables

List of Tables

Number of Products under Development for Bladder Cancer, H2 2016 29

Number of Products under Development for Bladder Cancer – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Development by Companies, H2 2016 (Contd..1) 32

Number of Products under Development by Companies, H2 2016 (Contd..2) 33

Number of Products under Development by Companies, H2 2016 (Contd..3) 34

Number of Products under Development by Companies, H2 2016 (Contd..4) 35

Number of Products under Development by Companies, H2 2016 (Contd..5) 36

Number of Products under Development by Companies, H2 2016 (Contd..6) 37

Number of Products under Development by Companies, H2 2016 (Contd..7) 38

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Comparative Analysis by Late Stage Development, H2 2016 40

Comparative Analysis by Clinical Stage Development, H2 2016 41

Comparative Analysis by Early Stage Development, H2 2016 42

Products under Development by Companies, H2 2016 43

Products under Development by Companies, H2 2016 (Contd..1) 44

Products under Development by Companies, H2 2016 (Contd..2) 45

Products under Development by Companies, H2 2016 (Contd..3) 46

Products under Development by Companies, H2 2016 (Contd..4) 47

Products under Development by Companies, H2 2016 (Contd..5) 48

Products under Development by Companies, H2 2016 (Contd..6) 49

Products under Development by Companies, H2 2016 (Contd..7) 50

Products under Development by Companies, H2 2016 (Contd..8) 51

Products under Development by Companies, H2 2016 (Contd..9) 52

Products under Development by Companies, H2 2016 (Contd..10) 53

Products under Investigation by Universities/Institutes, H2 2016 54

Bladder Cancer – Pipeline by 4SC AG, H2 2016 55

Bladder Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 56

Bladder Cancer – Pipeline by ADC Therapeutics SA, H2 2016 57

Bladder Cancer – Pipeline by Agenus Inc, H2 2016 58

Bladder Cancer – Pipeline by Altor BioScience Corporation, H2 2016 59

Bladder Cancer – Pipeline by AndroScience Corporation, H2 2016 60

Bladder Cancer – Pipeline by APIM Therapeutics AS, H2 2016 61

Bladder Cancer – Pipeline by Arno Therapeutics, Inc., H2 2016 62

Bladder Cancer – Pipeline by Astellas Pharma Inc., H2 2016 63

Bladder Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2016 64

Bladder Cancer – Pipeline by Aura Biosciences, Inc., H2 2016 65

Bladder Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 66

Bladder Cancer – Pipeline by Azaya Therapeutics, Inc., H2 2016 67

Bladder Cancer – Pipeline by Bavarian Nordic A/S, H2 2016 68

Bladder Cancer – Pipeline by Bayer AG, H2 2016 69

Bladder Cancer – Pipeline by BioCancell Ltd, H2 2016 70

Bladder Cancer – Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 71

Bladder Cancer – Pipeline by Bioncotech Therapeutics SL, H2 2016 72

Bladder Cancer – Pipeline by Biotest AG, H2 2016 73

Bladder Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 74

Bladder Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 75

Bladder Cancer – Pipeline by Celgene Corporation, H2 2016 76

Bladder Cancer – Pipeline by Cellceutix Corporation, H2 2016 77

Bladder Cancer – Pipeline by Celldex Therapeutics, Inc., H2 2016 78

Bladder Cancer – Pipeline by Celprogen, Inc., H2 2016 79

Bladder Cancer – Pipeline by Celsion Corporation, H2 2016 80

Bladder Cancer – Pipeline by Codagenix, Inc., H2 2016 81

Bladder Cancer – Pipeline by Cold Genesys, Inc., H2 2016 82

Bladder Cancer – Pipeline by Corvus Pharmaceuticals Inc, H2 2016 83

Bladder Cancer – Pipeline by CytomX Therapeutics, Inc., H2 2016 84

Bladder Cancer – Pipeline by DormaTarg, Inc., H2 2016 85

Bladder Cancer – Pipeline by Eisai Co., Ltd., H2 2016 86

Bladder Cancer – Pipeline by Eleven Biotherapeutics Inc., H2 2016 87

Bladder Cancer – Pipeline by Eli Lilly and Company, H2 2016 88

Bladder Cancer – Pipeline by Elsalys Biotech SAS, H2 2016 89

Bladder Cancer – Pipeline by enGene, Inc, H2 2016 90

ancer – Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 91

Bladder Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 93

Bladder Cancer – Pipeline by Five Prime Therapeutics, Inc., H2 2016 94

Bladder Cancer – Pipeline by Gene Signal International SA, H2 2016 95

Bladder Cancer – Pipeline by Genmab A/S, H2 2016 96

Bladder Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 97

Bladder Cancer – Pipeline by H3 Biomedicine Inc., H2 2016 98

Bladder Cancer – Pipeline by Hamlet Pharma AB, H2 2016 99

Bladder Cancer – Pipeline by Heat Biologics, Inc., H2 2016 100

Bladder Cancer – Pipeline by HEC Pharm Co., Ltd., H2 2016 101

Bladder Cancer – Pipeline by Hutchison MediPharma Limited, H2 2016 102

Bladder Cancer – Pipeline by Idera Pharmaceuticals, Inc., H2 2016 103

Bladder Cancer – Pipeline by ImmuNext, Inc., H2 2016 104

Bladder Cancer – Pipeline by Immunocore Limited, H2 2016 105

Bladder Cancer – Pipeline by Immunomedics, Inc., H2 2016 106

Bladder Cancer – Pipeline by Immupharma Plc, H2 2016 107

Bladder Cancer – Pipeline by InteRNA Technologies B.V., H2 2016 108

Bladder Cancer – Pipeline by Johnson & Johnson, H2 2016 109

Bladder Cancer – Pipeline by LipoMedix Pharmaceutical Inc., H2 2016 110

Bladder Cancer – Pipeline by MacroGenics, Inc., H2 2016 111

Bladder Cancer – Pipeline by MaxiVAX SA, H2 2016 112

Bladder Cancer – Pipeline by Meabco A/S, H2 2016 113

Bladder Cancer – Pipeline by Medicenna Therapeutics, Inc., H2 2016 114

Bladder Cancer – Pipeline by MedImmune LLC, H2 2016 115

Bladder Cancer – Pipeline by Merck & Co., Inc., H2 2016 116

Bladder Cancer – Pipeline by Merck KGaA, H2 2016 117

Bladder Cancer – Pipeline by Mirati Therapeutics Inc., H2 2016 118

Bladder Cancer – Pipeline by Mirna Therapeutics, Inc., H2 2016 119

Bladder Cancer – Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016 120

Bladder Cancer – Pipeline by Moleculin Biotech Inc, H2 2016 121

Bladder Cancer – Pipeline by NanoCarrier Co., Ltd., H2 2016 122

Bladder Cancer – Pipeline by Nektar Therapeutics, H2 2016 123

Bladder Cancer – Pipeline by NuCana BioMed Limited, H2 2016 124

Bladder Cancer – Pipeline by Omeros Corporation, H2 2016 125

Bladder Cancer – Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016 126

Bladder Cancer – Pipeline by Oncolytics Biotech Inc., H2 2016 127

Bladder Cancer – Pipeline by OncoTherapy Science, Inc., H2 2016 128

Bladder Cancer – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 129

Bladder Cancer – Pipeline by Optimum Therapeutics, LLC, H2 2016 130

Bladder Cancer – Pipeline by Pfizer Inc., H2 2016 131

Bladder Cancer – Pipeline by Pharma Mar, S.A., H2 2016 132

Bladder Cancer – Pipeline by Philogen S.p.A., H2 2016 133

Bladder Cancer – Pipeline by Plexxikon Inc., H2 2016 134

Bladder Cancer – Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 135

Bladder Cancer – Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 136

Bladder Cancer – Pipeline by PsiOxus Therapeutics Limited, H2 2016 137

Bladder Cancer – Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 138

Bladder Cancer – Pipeline by Rodos BioTarget GmbH, H2 2016 139

Bladder Cancer – Pipeline by Sanofi, H2 2016 140

Bladder Cancer – Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 141

Bladder Cancer – Pipeline by Serometrix, LLC, H2 2016 142

Bladder Cancer – Pipeline by Shionogi & Co., Ltd., H2 2016 143

Bladder Cancer – Pipeline by Sillajen Biotherapeutics, H2 2016 144

Bladder Cancer – Pipeline by Sorrento Therapeutics Inc, H2 2016 145

Bladder Cancer – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 146

Bladder Cancer – Pipeline by Stemline Therapeutics, Inc., H2 2016 147

Bladder Cancer – Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016 148

Bladder Cancer – Pipeline by Synovo GmbH, H2 2016 149

Bladder Cancer – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 150

Bladder Cancer – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 151

Bladder Cancer – Pipeline by Taris Biomedical LLC, H2 2016 152

Bladder Cancer – Pipeline by Telormedix SA, H2 2016 153

Bladder Cancer – Pipeline by TesoRx Pharma LLC, H2 2016 154

Bladder Cancer – Pipeline by Theravectys SA, H2 2016 155

Bladder Cancer – Pipeline by Theryte Limited, H2 2016 156

Bladder Cancer – Pipeline by Transgene SA, H2 2016 157

Bladder Cancer – Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 158

Bladder Cancer – Pipeline by Vakzine Projekt Management GmbH, H2 2016 159

Bladder Cancer – Pipeline by Vault Pharma Inc., H2 2016 160

Bladder Cancer – Pipeline by Vaxeal Holding SA, H2 2016 161

Bladder Cancer – Pipeline by Vaxiion Therapeutics, Inc., H2 2016 162

Bladder Cancer – Pipeline by Viralytics Ltd., H2 2016 163

Assessment by Monotherapy Products, H2 2016 164

Assessment by Combination Products, H2 2016 165

Number of Products by Stage and Target, H2 2016 167

Number of Products by Stage and Mechanism of Action, H2 2016 175

Number of Products by Stage and Route of Administration, H2 2016 184

Number of Products by Stage and Molecule Type, H2 2016 186

Bladder Cancer – Dormant Projects, H2 2016 713

Bladder Cancer – Dormant Projects (Contd..1), H2 2016 714

Bladder Cancer – Dormant Projects (Contd..2), H2 2016 715

Bladder Cancer – Dormant Projects (Contd..3), H2 2016 716

Bladder Cancer – Dormant Projects (Contd..4), H2 2016 717

Bladder Cancer – Dormant Projects (Contd..5), H2 2016 718

Bladder Cancer – Dormant Projects (Contd..6), H2 2016 719

Bladder Cancer – Dormant Projects (Contd..7), H2 2016 720

Bladder Cancer – Dormant Projects (Contd..8), H2 2016 721

Bladder Cancer – Dormant Projects (Contd..9), H2 2016 722

Bladder Cancer – Discontinued Products, H2 2016 723

List of Figures

List of Figures

Number of Products under Development for Bladder Cancer, H2 2016 29

Number of Products under Development for Bladder Cancer – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Comparative Analysis by Late Stage Development, H2 2016 40

Comparative Analysis by Clinical Stage Development, H2 2016 41

Comparative Analysis by Early Stage Products, H2 2016 42

Assessment by Monotherapy Products, H2 2016 164

Assessment by Combination Products, H2 2016 165

Number of Products by Top 10 Targets, H2 2016 166

Number of Products by Stage and Top 10 Targets, H2 2016 166

Number of Products by Top 10 Mechanism of Actions, H2 2016 174

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 174

Number of Products by Top 10 Routes of Administration, H2 2016 183

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 183

Number of Products by Top 10 Molecule Types, H2 2016 185

Number of Products by Stage and Top 10 Molecule Types, H2 2016 185

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports